Historical Valuation
Harmony Biosciences Holdings Inc (HRMY) is now in the Undervalued zone, suggesting that its current forward PE ratio of 10.04 is considered Undervalued compared with the five-year average of 17.71. The fair price of Harmony Biosciences Holdings Inc (HRMY) is between 62.19 to 123.46 according to relative valuation methord. Compared to the current price of 38.55 USD , Harmony Biosciences Holdings Inc is Undervalued By 38.01%.
Relative Value
Fair Zone
62.19-123.46
Current Price：38.55
38.01%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Harmony Biosciences Holdings Inc (HRMY) has a current Price-to-Book (P/B) ratio of 2.58. Compared to its 3-year average P/B ratio of 3.65 , the current P/B ratio is approximately -29.39% higher. Relative to its 5-year average P/B ratio of 7.79, the current P/B ratio is about -66.91% higher. Harmony Biosciences Holdings Inc (HRMY) has a Forward Free Cash Flow (FCF) yield of approximately 13.79%. Compared to its 3-year average FCF yield of 10.81%, the current FCF yield is approximately 27.58% lower. Relative to its 5-year average FCF yield of 7.77% , the current FCF yield is about 77.57% lower.
P/B
Median3y
3.65
Median5y
7.79
FCF Yield
Median3y
10.81
Median5y
7.77
Competitors Valuation Multiple
AI Analysis for HRMY
The average P/S ratio for HRMY competitors is 7.56, providing a benchmark for relative valuation. Harmony Biosciences Holdings Inc Corp (HRMY.O) exhibits a P/S ratio of 2.23, which is -70.47% above the industry average. Given its robust revenue growth of 28.71%, this premium appears sustainable.
Performance Decomposition
AI Analysis for HRMY
1Y
3Y
5Y
Market capitalization of HRMY increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of HRMY in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is HRMY currently overvalued or undervalued?
Harmony Biosciences Holdings Inc (HRMY) is now in the Undervalued zone, suggesting that its current forward PE ratio of 10.04 is considered Undervalued compared with the five-year average of 17.71. The fair price of Harmony Biosciences Holdings Inc (HRMY) is between 62.19 to 123.46 according to relative valuation methord. Compared to the current price of 38.55 USD , Harmony Biosciences Holdings Inc is Undervalued By 38.01% .
What is Harmony Biosciences Holdings Inc (HRMY) fair value?
HRMY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Harmony Biosciences Holdings Inc (HRMY) is between 62.19 to 123.46 according to relative valuation methord.
How does HRMY's valuation metrics compare to the industry average?
The average P/S ratio for HRMY's competitors is 7.56, providing a benchmark for relative valuation. Harmony Biosciences Holdings Inc Corp (HRMY) exhibits a P/S ratio of 2.23, which is -70.47% above the industry average. Given its robust revenue growth of 28.71%, this premium appears sustainable.
What is the current P/B ratio for Harmony Biosciences Holdings Inc (HRMY) as of Jan 10 2026?
As of Jan 10 2026, Harmony Biosciences Holdings Inc (HRMY) has a P/B ratio of 2.58. This indicates that the market values HRMY at 2.58 times its book value.
What is the current FCF Yield for Harmony Biosciences Holdings Inc (HRMY) as of Jan 10 2026?
As of Jan 10 2026, Harmony Biosciences Holdings Inc (HRMY) has a FCF Yield of 13.79%. This means that for every dollar of Harmony Biosciences Holdings Inc’s market capitalization, the company generates 13.79 cents in free cash flow.
What is the current Forward P/E ratio for Harmony Biosciences Holdings Inc (HRMY) as of Jan 10 2026?
As of Jan 10 2026, Harmony Biosciences Holdings Inc (HRMY) has a Forward P/E ratio of 10.04. This means the market is willing to pay $10.04 for every dollar of Harmony Biosciences Holdings Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Harmony Biosciences Holdings Inc (HRMY) as of Jan 10 2026?
As of Jan 10 2026, Harmony Biosciences Holdings Inc (HRMY) has a Forward P/S ratio of 2.23. This means the market is valuing HRMY at $2.23 for every dollar of expected revenue over the next 12 months.